Frequency of COVID‐19 vaccine side effects and its associated factors among the vaccinated population of Pakistan: A cross‐sectional study

Yasmin, Farah; Najeeb, Hala; Siddiqui, Hasan Fareed; Asghar, Muhammad Sohaib; Awan, Hashir Ali; Usama, Rana Muhammad; Allahuddin, Zoha; Tahir, Muhammad Junaid; Ullah, Kaleem; Eljack, Mohammed Mahmmoud Fadelallah

doi:10.1002/hsr2.1071

Cited by 7 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first dosage of the vaccine was associated with a higher likelihood of side effects than the second dose. Comorbidities and prior COVID-19 infection were shown to be independent (p = 0.707) of the prevalence of adverse effects [23]. This conclusion was equivalent to another study performed in Saudi Arabia; conversely, UK research by Cristina et al presenteda low incidence of injection site pain [24,25].Likewise, these findings were similar to those of the present study and revealed that side effects were more pronounced in children than in adult participants.…”

Section: Discussionsupporting

confidence: 91%

Common Local and Systemic Side Effects of Sinovac Covid-19 Vaccine Among Children and Adult Participants

Ata,

Rafique,

Ameer

et al. 2023

PJMHS

View full text Add to dashboard Cite

Objective: Vaccination is one of the primary measures for halting the COVID-19 outbreak. Although there are several vaccines in use around the globe, little is known about the Sinovac vaccine's efficacy and side effects. Therefore, the purpose of this study was to investigate the reported side effects of the Sinovac vaccine in children and adult participants. Methodology: This was a multi-centered, cross-sectional study that was performed, using a non-probability sampling method. The study’s duration was about eight months, from March 1, 2022, to October 31, 2022 after taking approval. The study included 450 participants, including 225 children and 225 adults, who had either received the first or second dose of the Sinovac vaccination. Age, weight, height, and duration of diabetes and hypertension were documented as means and standard deviations. Frequencies and percentages were documented for demographic features. A chi-square test was used to determine the association between local and systemic side effects among children and adult participants. Results: The study findings showed that out of 450 participants, One hundred forty (62.2%) male participants and 85(37.8%) female participants were under the age of 18, and 163(72.4%) male participants and 62(27.6%) female participants were above the age of 18 years, with a significant difference observed among them (p=0.021). Following the first dose of the Sinovac vaccine, fever was the most frequently reported side effect in 123(54.7%) children and 81(36.0%) adult participants, with a substantial association noticed among them (p<0.001). Similarly, following the 2nd dose of the Sinovac vaccine, fever was the commonly reported side effect in 94(41.8%) children and 61(27.1%) adult participants, with a substantial association noticed among them (p=0.001). Conclusion: This study concluded that the most frequently reported side effect was fever in both children and adult participants following receiving the first and second doses of Sinovac vaccines. Moreover, pain and swelling at the injection site were the only local side effects observed. Additionally, the observed side effects were more pronounced after the first dose as compared to the second dose. Keywords: Sinovac vaccine, fever, pain, swelling injection site.

show abstract

Section: Discussionsupporting

confidence: 91%

Common Local and Systemic Side Effects of Sinovac Covid-19 Vaccine Among Children and Adult Participants

Ata,

Rafique,

Ameer

et al. 2023

PJMHS

View full text Add to dashboard Cite

show abstract

“…In particular, for both cohorts, the most frequently reported local solicited ADR following both the first vaccination cycle and the booster dose was injection site pain. As for systemic solicited ADRs, fatigue, headache, malaise, and myalgia were the most commonly reported; such findings are in line with previously published articles [ 26 , 27 , 28 ].…”

Section: Discussionsupporting

confidence: 90%

Safety Monitoring of COVID-19 Vaccines in Persons with Prior SARS-CoV-2 Infection: A European Multi-Country Study

Ciccimarra,

Luxi,

Bellitto

et al. 2024

Vaccines

View full text Add to dashboard Cite

In all pivotal trials of COVID-19 vaccines, the history of previous SARS-CoV-2 infection was mentioned as one of the main exclusion criteria. In the absence of clinical trials, observational studies are the primary source for evidence generation. This study aims to describe the patient-reported adverse drug reactions (ADRs) following the first COVID-19 vaccination cycle, as well as the administration of booster doses of different vaccine brands, in people with prior SARS-CoV-2 infection, as compared to prior infection-free matched cohorts of vaccinees. A web-based prospective study was conducted collecting vaccinee-reported outcomes through electronic questionnaires from eleven European countries in the period February 2021–February 2023. A baseline questionnaire and up to six follow-up questionnaires collected data on the vaccinee’s characteristics, as well as solicited and unsolicited adverse reactions. Overall, 3886 and 902 vaccinees with prior SARS-CoV-2 infection and having received the first dose or a booster dose, respectively, were included in the analysis. After the first dose or booster dose, vaccinees with prior SARS-CoV-2 infection reported at least one ADR at a higher frequency than those matched without prior infection (3470 [89.6%] vs. 2916 [75.3%], and 614 [68.2%] vs. 546 [60.6%], respectively). On the contrary side, after the second dose, vaccinees with a history of SARS-CoV-2 infection reported at least one ADR at a lower frequency, compared to matched controls (1443 [85.0%] vs. 1543 [90.9%]). The median time to onset and the median time to recovery were similar across all doses and cohorts. The frequency of adverse reactions was higher in individuals with prior SARS-CoV-2 infection who received Vaxzevria as the first dose and Spikevax as the second and booster doses. The frequency of serious ADRs was low for all doses and cohorts. Data from this large-scale prospective study of COVID-19 vaccinees could be used to inform people as to the likelihood of adverse effects based on their history of SARS-CoV-2 infection, age, sex, and the type of vaccine administered. In line with pivotal trials, the safety profile of COVID-19 vaccines was also confirmed in people with prior SARS-CoV-2 infection.

show abstract

“… 25–27 Moreover, a number of studies evaluating the side effects of COVID−19 vaccines in Pakistan have revealed a satisfactory safety profile among vaccine recipients. 28–30 …”

Section: Discussionmentioning

confidence: 99%

Trajectory of COVID-19 vaccine hesitancy post-vaccination and public’s intention to take booster vaccines: A cross-sectional analysis

Salman,

Mallhi,

Khan

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Vaccine hesitancy (VH) is not a new phenomenon in Pakistan and is regarded as one of the primary causes of unsatisfactory vaccination campaigns. This study determined post-vaccination COVID−19 VH, factors influencing COVID−19 vaccine uptake, and public’s intent to receive booster vaccinations. A cross-sectional study was conducted among adult population of Lahore, Pakistan. Participants were recruited via convenience sampling between March and May 2022. SPSS version 22 was used for the data analysis. A total of 650 participants were included in the study (age = 28.1 ± 9.7 years; male-to-female ratio nearly 1: 1). The majority of participants received Sinopharm followed by Sinovac vaccine. The top three reasons of vaccine uptake were “only vaccinated individuals are allowed at the workplace, and educational institutes” (Relative importance index (RII) = 0.749), “only vaccinated people are allowed to go to markets, malls and other public places” (RII = 0.746), and “protect myself from the infection” (RII = 0.742). The mean COVID−19 VH score was 24.5 ± 6.2 (95% CI 23.9–24.9), with not being pro-vaccines and poor economic status were the significant predictors of COVID−19 vaccine hesitancy among immunized individuals ( p < .05). Acceptance of booster vaccines was negatively associated with younger age and a lower level of education. Furthermore, being pro-vaccine was associated with a greater likelihood of accepting booster vaccines ( p = .001). The Pakistani public continues to express VH toward COVID−19 vaccines. Therefore, aggressive measures must be taken to combat the community factors that contribute to it.

show abstract

Frequency of COVID‐19 vaccine side effects and its associated factors among the vaccinated population of Pakistan: A cross‐sectional study

Cited by 7 publications

References 31 publications

Common Local and Systemic Side Effects of Sinovac Covid-19 Vaccine Among Children and Adult Participants

Common Local and Systemic Side Effects of Sinovac Covid-19 Vaccine Among Children and Adult Participants

Safety Monitoring of COVID-19 Vaccines in Persons with Prior SARS-CoV-2 Infection: A European Multi-Country Study

Trajectory of COVID-19 vaccine hesitancy post-vaccination and public’s intention to take booster vaccines: A cross-sectional analysis

Contact Info

Product

Resources

About